01.18.23 -- Digital Vs. Decentralized Trials: Meeting The Implementation Challenges

Digital clinical trials, which have gained momentum since the onset of the pandemic, have the potential to address many of the inefficiencies of traditional trials. This article defines digital clinical trials and how they differ from decentralized clinical trials, as well as how to meet implementation challenges.

Explore why the clinical trials industry is shifting even further toward the routine incorporation of home visits into their studies.

To run clinical trials quickly, safely, and with high data integrity, learn why it is effective to assess trials by degree of touch.

The COVID-19 pandemic is helping create a “new normal” for the life sciences industry regarding the policies, procedures, and processes of clinical trials. In Part 1, we discussed five factors that more directly impact the clinical trial process and patients. In Part 2, we will discuss six factors that focus on organizational structure and the broader industry. 

Discover why having the right CRO for a digital therapeutics study can have a serious impact on the trial efficiency and regulatory success of the study. 

Personalized medicine represents unprecedented potential benefits for patients, yet it also brings new challenges for those conducting the clinical trials. Explore these challenges in the available case study.

Gain insight into how small and midsize pharma sponsors can successfully navigate the challenges of Japan's clinical, regulatory, and cultural environment, especially since in recent years the country has worked to ease market barriers and streamline approval processes.

The period from pre-site visit to contract and budget execution typically takes many months and represents the majority of study start-up cycle time. Read about an effective strategy to shorten long contract cycle times.

Cenduit IRT study design teams took on the challenges pressing biopharmaceutical industry sponsors as they worked to digitally enable sites and speed up time to first-patient-in for COVID-19 therapeutic and vaccine trials.

Explore the logistical and distribution risk management factors that need to be considered when planning an EU Compassionate Use Program, especially when faced with COVID-19 closures and challenges.

In this webinar, clinical operations teams, project managers, and clinical research coordinators will learn best practices to optimize clinical supply chain management.

Phlexglobal’s unmatched expertise working in any eTMF system is enabling busy study teams to assess, prevent, and manage risk across the entire TMF spectrum – improving inspection-readiness with less effort.

Cmed is highly experienced in the management of cell and gene therapy clinical trials, whether in oncology, rare diseases, or other therapeutic areas.

Veristat has built a team of scientific-minded experts who have supported more than 300 projects for endocrine/metabolic disorder treatments and prepared over 30 marketing applications, 60% of which have been approved or authorized to date.